Interaction of Diamine Oxidase with Psychostimulant Drugs for ADHD Management.
Yaiza TobajasMarc Alemany-FornésIris Samarra MestreJordi Romero-GiménezMaria TintoréAntoni Del PinoNuria CanelaJosep Maria Del BasNàdia Ortega-OlivéCarlos de LeceaXavier EscotéPublished in: Journal of clinical medicine (2023)
Histamine intolerance occurs when there is an imbalance between histamine production and the capacity for histamine degradation. Diamine oxidase (DAO) is the main enzyme for the catabolism of ingested histamine degradation in the gastrointestinal tract and its deficiency has been linked to allergy-like symptoms. Psychostimulant drugs are commonly used to treat Attention Deficit Hyperactivity Disorder (ADHD), but their interaction with DAO is not well characterized. In this work, we evaluated the effects of psychostimulant drugs (methylphenidate and lisdexamfetamine) on in vitro DAO activity and in the human cell line of enterocytes (Caco-2), evaluating DAO expression (mRNA and protein) and DAO activity. Methylphenidate and lisdexamfetamine did not repress the in vitro DAO activity. In addition, in Caco-2 cells, lisdexamfetamine promoted a strong upregulation of DAO mRNA levels, whereas methylphenidate tended to induce DAO activity. To sum up, methylphenidate and lisdexamfetamine treatments do not reduce DAO activity. These findings could be useful for physicians prescribing these two drugs to ADHD patients affected by DAO deficiency.
Keyphrases
- attention deficit hyperactivity disorder
- autism spectrum disorder
- working memory
- primary care
- endothelial cells
- emergency department
- binding protein
- induced apoptosis
- cell proliferation
- signaling pathway
- ejection fraction
- oxidative stress
- chronic kidney disease
- newly diagnosed
- physical activity
- depressive symptoms
- prognostic factors
- patient reported
- sleep quality
- atopic dermatitis
- infectious diseases